Circulating Tumor DNA Status and Adjuvant Chemotherapy in Resected Colorectal Liver Metastases

Дата публикации: 03-07-2026 00:00:00

This prognostic study evaluates the association between circulating tumor DNA–defined molecular residual disease and survival outcomes and whether molecular residual disease status is associated with differential benefit from adjuvant chemotherapy in resected colorectal liver metastases.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Organ Preservation and QOL After Total Neoadjuvant Treatment in Rectal Cancer	0	7.94	15-10-2026
2	Immune Checkpoint Inhibitor–Based Downstaging Therapy for Hepatocellular Carcinoma	0	7.13	01-10-2026
3	Tumor Debulking Plus Chemotherapy for Multiorgan Metastatic Colorectal Cancer—Reply	0	6.33	18-08-2026
4	Liquid Biopsies for Cancer	0	8.31	10-08-2026
5	Circulating Methylated SEPT9 for Detection of Hepatocellular Carcinoma in Cirrhosis	0	7	02-07-2026
6	Effect of Neoadjuvant Therapy on Postoperative Complications in Colorectal Cancer: A Multicenter Prospective Propensity-Matched Cohort Study	0	5	16-07-2026
7	Beyond Tumor Size, Toward Meaningful Patient Outcomes	0	8.26	08-10-2026
8	Addition of High-Dose Vitamin D 3 to Standard Treatment for Metastatic Colorectal Cancer	0	13.41	03-08-2026
9	Race, Secondary Treatment, and Survival in Localized Prostate Cancer	0	5.24	21-07-2026
10	Colorectal Cancer Risk Factors in Adults in Nigeria	0	10.34	03-08-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 7. Источник: jamanetwork.com.